
    
      Subjects will be between 18 and 65 years old, have at least 5 current symptoms of inattentive
      or impulsive-hyperactive traits, and childhood onset of ADHD symptoms, defined as two
      symptoms of inattentive or of impulsive/hyperactive traits by the age of 12. Subjects will
      also have a score of 20 or more on the Adult ADHD Investigator Symptom Report Scale (AISRS).

      The investigators will exclude individuals who are contraindicated by current FDA label
      recommendations, which elaborates appropriate use of solriamfetol for individuals with sleep
      apnea and narcolepsy.

      This will be a a six week, double blind, dose-optimization study. After giving informed
      consent to participate, participants will undergo a comprehensive assessment including a
      psychiatric assessment reviewing eligibility.
    
  